Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ARCT

Arcturus Therapeutics Holdings Inc

Apr 13 • 04:00PM ET

8.46

+0.10 1.20 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX PFE NVAX DVAX INO VXRT ALT ADMA ADAP

| Held by: ARKG VTI IWM VXF IBB IWN SCHA VTWO PRFZ DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.39	Insider Own	8.43%	Shs Outstand	28.41M	Perf Week	2.92%
Market Cap	240.46M	Forward P/E	-	EPS next Y	-4.20	Insider Trans	0.00%	Shs Float	26.03M	Perf Month	20.86%
Enterprise Value	34.55M	PEG	-	EPS next Q	-1.01	Inst Own	76.81%	Short Float	24.78%	Perf Quarter	24.78%
Income	-65.78M	P/S	3.58	EPS this Y	-68.40%	Inst Trans	-8.59%	Short Ratio	12.75	Perf Half Y	-57.01%
Sales	67.22M	P/B	1.12	EPS next Y	-3.89%	ROA	-21.39%	Short Interest	6.45M	Perf YTD	38.01%
Book/sh	7.53	P/C	1.04	EPS next 5Y	15.05%	ROE	-28.92%	52W High	24.17 -65.00%	Perf Year	-12.78%
Cash/sh	8.12	P/FCF	-	EPS past 3/5Y	- 7.53%	ROIC	-28.02%	52W Low	5.85 44.62%	Perf 3Y	-70.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-31.15% 47.77%	Gross Margin	95.41%	Volatility	5.48% 6.04%	Perf 5Y	-78.56%
Dividend TTM	-	EV/Sales	0.51	EPS Y/Y TTM	20.51%	Oper. Margin	-111.51%	ATR (14)	0.49	Perf 10Y	-72.34%
Dividend Ex-Date	-	Quick Ratio	6.64	Sales Y/Y TTM	-51.43%	Profit Margin	-97.86%	RSI (14)	64.46	Recom	1.46
Dividend Gr. 3/5Y	- -	Current Ratio	6.64	EPS Q/Q	6.92%	SMA20	14.24%	Beta	2.52	Target Price	23.30
Payout	-	Debt/Eq	0.12	Sales Q/Q	-85.33%	SMA50	12.91%	Rel Volume	0.50	Prev Close	8.36
Employees	111	LT Debt/Eq	0.10	Earnings	Mar 03 AMC	SMA200	-25.50%	Avg Volume	506.05K	Price	8.46
IPO	May 22, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-32.58% -54.75%	Trades		Volume	255,075	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-26	Initiated	B. Riley Securities	Buy	$22
Jan-23-26	Initiated	Roth Capital	Buy	$20
Oct-24-25	Downgrade	H.C. Wainwright	Buy → Neutral	$12
Oct-23-25	Downgrade	Citigroup	Buy → Neutral	$12
Oct-22-25	Downgrade	Guggenheim	Buy → Neutral
Sep-04-25	Resumed	H.C. Wainwright	Buy	$60
May-28-25	Initiated	Scotiabank	Sector Outperform	$32
Jan-28-25	Initiated	BTIG Research	Buy	$41
Aug-12-24	Initiated	Leerink Partners	Outperform	$70
Dec-13-23	Initiated	Canaccord Genuity	Buy	$90
Jul-24-23	Initiated	William Blair	Outperform	$71
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy	$19 → $51
Nov-14-22	Resumed	Wells Fargo	Overweight	$35
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform	$18
Nov-03-22	Upgrade	Citigroup	Neutral → Buy	$22 → $35
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight	$16 → $25
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight	$86 → $39
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral	$21 → $18
Apr-21-22	Downgrade	Citigroup	Buy → Neutral	$86 → $29

Show Previous Ratings

Mar-05-26 09:00AM	Arcturus Therapeutics to Attend Upcoming Investor Conference (Business Wire)
Mar-04-26 08:02PM	Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary (Moby)
12:01AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
Mar-03-26 06:02PM	Arcturus Therapeutics Q4 Earnings Call Highlights (MarketBeat) -5.27%
05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress (Business Wire)
Mar-02-26 08:15AM	Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates (Zacks)
07:20AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings (GuruFocus.com)
Feb-26-26 01:30PM	Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-17-26 04:01PM	Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 (Business Wire)
Feb-11-26 12:52PM	Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit (MarketBeat)
Feb-09-26 02:14PM	Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating (Insider Monkey)
Feb-02-26 09:54AM	Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets (Insider Monkey)
Jan-12-26 10:06PM	Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference (MarketBeat) +11.06%
Jan-10-26 12:00PM	1 Under-$10 Stock Set to Surge as Much as 963% in 2026 (Barchart)
05:30PM	Loading…
Jan-08-26 05:30PM	Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 07:58AM	Cathie Wood Dumps Tesla Again, Pours Millions Into This Tech Gaint (GuruFocus.com)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-24-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conference (Business Wire) +7.42%
Nov-11-25 12:03AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... (GuruFocus.com)
Nov-10-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:07PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
Nov-07-25 07:22AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings (GuruFocus.com) +5.19%
Nov-06-25 09:15AM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline (Zacks) -6.72%
Oct-28-25 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 (Business Wire) -6.70%
08:15AM	NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
09:34AM	Loading…
Oct-24-25 09:34AM	Coinbase, eBay upgraded: Wall Street's top analyst calls (The Fly) -6.50%
Oct-23-25 09:39AM	LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Cathie Wood Goes Shopping: 3 Stocks She Just Bought (Motley Fool)
Oct-22-25 04:09PM	Arcturus Crashes 50% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug (Investor's Business Daily) -50.17%
08:50AM	Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure (Zacks)
05:57AM	Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Oct-21-25 09:07AM	4 Stocks With Recent Price Strength to Maximize Your Gains (Zacks) +7.67%
Oct-15-25 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks)
08:50AM	Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-19-25 08:31AM	Cathie Wood Snaps Up $49 Million in This Little-Known Sports Company (GuruFocus.com)
06:50AM	Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Sep-01-25 09:55AM	Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross? (Zacks)
Aug-26-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Aug-11-25 06:55PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +30.73%
05:53PM	Arcturus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
Aug-08-25 05:30PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:26AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 08:20AM	Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 04:01PM	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 (Business Wire)
Jul-23-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire) +6.33%
Jun-30-25 11:00AM	Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program (Business Wire)
Jun-23-25 08:30AM	Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
Jun-03-25 09:55AM	Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet (Zacks)
May-29-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire) +7.70%
May-15-25 09:55AM	Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade (Zacks) +7.38%
May-13-25 08:44AM	Q1 2025 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... (GuruFocus.com)
May-12-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.56%
04:08PM	Arcturus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
May-09-25 09:39AM	Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result (GuruFocus.com)
May-05-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline (Zacks) -7.09%
Apr-22-25 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 (Business Wire) +10.64%
Apr-11-25 11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 08:00AM	Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 (Business Wire)
Mar-20-25 04:36PM	Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
Mar-07-25 11:16AM	Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
02:17AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
Mar-06-25 05:15PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress (Business Wire)
Mar-05-25 04:30PM	Arcturus Therapeutics to Present at Leerinks Global Healthcare Conference 2025 (Business Wire)
07:21AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-24-25 04:01PM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 (Business Wire) -6.08%
Feb-14-25 08:30AM	European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) +9.99%
Feb-04-25 08:30AM	Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate (Business Wire)
Jan-31-25 03:00AM	Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE, a Self-amplifying mRNA Vaccine Against COVID-19 (Business Wire)
Jan-30-25 04:01PM	Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-10-25 11:14AM	Arcturus Therapeutics launches Phase I Avian Influenza trials in US (Clinical Trials Arena) -5.12%
08:00AM	Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial (Business Wire)
Jan-06-25 04:01PM	Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency (Business Wire) +6.30% +9.23%
Dec-16-24 04:01PM	Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.64%
Dec-11-24 11:55AM	Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Nov-26-24 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-18-24 08:00PM	Arcturus Therapeutics to Present at Jefferies London Healthcare Conference (Business Wire) +11.00%
Nov-14-24 01:00AM	Meiji Seika Pharma Announces Investment in ARCALIS, Inc. (Business Wire)
Nov-11-24 04:01PM	Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial (Business Wire)
Nov-08-24 12:15PM	Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
02:29AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... (GuruFocus.com)
Nov-07-24 05:55PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:48PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
Nov-06-24 07:35AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-31-24 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 (Business Wire)
Oct-30-24 12:00PM	Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-23-24 04:00AM	A slow start for self-amplifying mRNA vaccines (Pharmaceutical Technology)

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARCT

Arcturus Therapeutics Holdings Inc

Upgrade your Finviz experience